Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
27 Aug 2024
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/molecular-partners-rethinks-tetra-specific-dosing-after-seeing-suboptimal-exposure-cancer
17 Jan 2023
// CLINICAL TRIALS ARENA
https://www.clinicaltrialsarena.com/news/molecular-myeloid-leukemia-therapy/
25 Aug 2022
// PRESS RELEASE
https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-reports-corporate-highlights-and-h1-2022
22 Jul 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/07/22/2484698/0/en/Molecular-Partners-AG-Shareholder-Update-Robbins-LLP-Reminds-Investors-of-Lead-Plaintiff-Deadline-in-Class-Action-Against-Molecular-Partners-AG-MOLN.html
12 May 2022
// PRESS RELEASE
https://investors.molecularpartners.com/news-releases/news-release-details/interim-management-statement-q1-2022-molecular-partners-cash
11 May 2022
// PRESS RELEASE
https://investors.molecularpartners.com/news-releases/news-release-details/molecular-partners-participate-upcoming-healthcare-investor
Details:
MP0533 is a T-cell engager, leveraging the cell surface protein CD3 as a powerful immune activator, complemented by novel control mechanisms designed to help direct CD3-mediated cytotoxicity with heightened precision. It is being studied for AML.
Lead Product(s): MP0533
Therapeutic Area: Oncology Brand Name: MP0533
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details : MP0533 is a T-cell engager, leveraging the cell surface protein CD3 as a powerful immune activator, complemented by novel control mechanisms designed to help direct CD3-mediated cytotoxicity with heightened precision. It is being studied for AML.
Brand Name : MP0533
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 16, 2023
Details:
MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation.
Lead Product(s): MP0310
Therapeutic Area: Oncology Brand Name: MP0310
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Molecular Partners to Regain Global Rights for MP0310 from Amgen
Details : MP0310 is a dual-targeted compound, targeting both FAP and 4-1BB, that has the potential to activate T-cells and other immune cells, specifically in the tumor microenvironment, aiming to avoid systemic side effects associated with 4-1BB activation.
Brand Name : MP0310
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 26, 2022
Details:
MP0420 (ensovibep) is a COVID-19 antiviral therapeutic candidate designed specifically to inactivate SARS-CoV-2 – the virus that causes COVID-19 – with extremely high potency that is preserved against novel variants.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2022
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MP0420 (ensovibep) is a COVID-19 antiviral therapeutic candidate designed specifically to inactivate SARS-CoV-2 – the virus that causes COVID-19 – with extremely high potency that is preserved against novel variants.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 23, 2022
Details:
Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of MP0420/SKO136 (ensovibep), a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Recipient: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Recipient : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Topline results from the randomized EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of MP0420/SKO136 (ensovibep), a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load r...
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 10, 2022
Details:
Laboratory studies using full Omicron pseudovirus confirm MP0420 (ensovibep), maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2021
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Laboratory studies using full Omicron pseudovirus confirm MP0420 (ensovibep), maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 12, 2021
Details:
In vitro data to-date demonstrate that ensovibep retains potency in inhibiting all known SARS-CoV-2 variants of concern, including the Delta variants. Ensovibep is the lead therapeutic candidate in Molecular Partners’ infectious disease pipeline.
Lead Product(s): Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2021
Lead Product(s) : Ensovibep,Remdesivir,Sotrovimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In vitro data to-date demonstrate that ensovibep retains potency in inhibiting all known SARS-CoV-2 variants of concern, including the Delta variants. Ensovibep is the lead therapeutic candidate in Molecular Partners’ infectious disease pipeline.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 16, 2021
Details:
In the results presented, neutralization assays demonstrate ensovibep’s ability to potently neutralize SARS-CoV-2 when testing the Wuhan or a reference strain.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the results presented, neutralization assays demonstrate ensovibep’s ability to potently neutralize SARS-CoV-2 when testing the Wuhan or a reference strain.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 20, 2021
Details:
The collaboration will combine Molecular Partners’ industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis. DARPins have great potential to enable robust, tumor-specific delivery of radioligands.
Lead Product(s): DARPin-conjugated Radioligand Therapies
Therapeutic Area: Oncology Brand Name: DARPin-RLTs
Study Phase: DiscoveryProduct Type: Large molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $580.0 million Upfront Cash: $20.0 million
Deal Type: Acquisition October 14, 2021
Lead Product(s) : DARPin-conjugated Radioligand Therapies
Therapeutic Area : Oncology
Highest Development Status : Discovery
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $580.0 million
Deal Type : Acquisition
Details : The collaboration will combine Molecular Partners’ industry-leading ability to rapidly generate high-affinity DARPins and the RLT capabilities and expertise of Novartis. DARPins have great potential to enable robust, tumor-specific delivery of radiolig...
Brand Name : DARPin-RLTs
Molecule Type : Large molecule
Upfront Cash : $20.0 million
October 14, 2021
Details:
Abicipar is a long-acting anti-VEGF DARPin® molecule which was invented by Molecular Partners and initially licensed to Allergan in 2011.
Lead Product(s): Abicipar Pegol
Therapeutic Area: Ophthalmology Brand Name: AGN-150998
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 09, 2021
Lead Product(s) : Abicipar Pegol
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Partnership
Molecular Partners to Regain Global Rights to Abicipar
Details : Abicipar is a long-acting anti-VEGF DARPin® molecule which was invented by Molecular Partners and initially licensed to Allergan in 2011.
Brand Name : AGN-150998
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 09, 2021
Details:
MP0420 is a clinical-stage candidate that is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ infectious disease program.
Lead Product(s): Ensovibep
Therapeutic Area: Infections and Infectious Diseases Brand Name: MP0420
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: J.P. Morgan
Deal Size: $63.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 15, 2021
Lead Product(s) : Ensovibep
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $63.8 million
Deal Type : Public Offering
Details : MP0420 is a clinical-stage candidate that is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ infectious disease program.
Brand Name : MP0420
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 15, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?